Abstract
Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1842-1851 |
| Number of pages | 10 |
| Journal | Current Pharmaceutical Biotechnology |
| Volume | 13 |
| Issue number | 9 |
| DOIs | |
| State | Published - Jul 2012 |
| Externally published | Yes |
Keywords
- Angiogenesis
- Cytokines
- Extracellular matrix
- Herpes simplex virus
- Immune response
- Oncolytic viruses
- Tumor microenvironment
ASJC Scopus subject areas
- Biotechnology
- Pharmaceutical Science
